{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:46Z","timestamp":1753891966634,"version":"3.41.2"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>In the last decade, there have been substantial improvements in the outcome of the management of metastatic hormone-sensitive prostate cancer (mHSPC) following the development of several novel agents as well as by combining several therapeutic strategies. Although the overall survival (OS) of mHSPC is shown to improve with intense androgen deprivation therapy (ADT), combined with docetaxel, as well as other novel hormonal therapy agents, or alongside local intervention to the primary neoplasm. Notably, luteinizing hormone-releasing hormone (LHRH) antagonists are known to cause fewer cardiovascular side effects compared with LHRH agonists. Thus, in this mini review, we explore the different approaches in the management of mHSPC, with the aim that we may provide useful information for both basic scientists and clinicians when managing relevant clinical situations.<\/jats:p>","DOI":"10.3389\/fonc.2022.913438","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T04:43:24Z","timestamp":1660797804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancements in the treatment of metastatic hormone-sensitive prostate cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Hengping","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and united states, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112330-20210616-00330","article-title":"Where are the future directions in prostate cancer diagnosis and treatment in Asia","volume":"42","author":"Dingwei","year":"2021","journal-title":"Chin J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \"Docetaxel era\": Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13600","article-title":"Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study","volume":"109","author":"Ozono","year":"2018","journal-title":"Cancer Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.07.002","article-title":"The efficacy and safety of relugolix compared with degarelix in advanced prostate cancer patients: A network meta-analysis of randomized trials","volume":"5","author":"Sari Motlagh","year":"2022","journal-title":"Eur Urol Oncol"},{"volume-title":"National comprehensive cancer network (NCCN) prostate cancer guidelines","year":"2021","author":"Schaeffer","key":"B11"},{"volume-title":"EAU-ESUR-ESTRO-SIOG-Guidelines-On-Prostate-Cancer","year":"","author":"Mottet","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: Post hoc analysis of phase 3 LATITUDE study","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.11.026","article-title":"Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study","volume":"162","author":"Baciarello","year":"2022","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \"High-\" and \"Low-risk\" metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001568","article-title":"Efficacy of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread: ARCHES Post hoc analyses","volume":"205","author":"Armstrong","year":"2021","journal-title":"J Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00436-y","article-title":"Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk","volume":"25","author":"Azad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001841","article-title":"Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: Analysis of pain and fatigue in the phase 3 TITAN study","volume":"206","author":"Agarwal","year":"2021","journal-title":"J Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14447","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study","volume":"28","author":"Uemura","year":"2021","journal-title":"Int J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_64_21","article-title":"Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial","volume":"24","author":"Chung","year":"2022","journal-title":"Asian J Androl"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-019-0195-5","article-title":"A review of prostate cancer treatment impact on the CNS and cognitive function","volume":"23","author":"Ryan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Christian Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14711","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a cochrane review","volume":"124","author":"Sathianathen","year":"2019","journal-title":"BJU Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0284-3","article-title":"Cytoreductive treatment strategies for de novo metastatic prostate cancer","volume":"17","author":"Connor","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00339-y","article-title":"Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer","volume":"24","author":"Morgan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.089","article-title":"Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study","volume":"193","author":"Heidenreich","year":"2015","journal-title":"J Urol"},{"key":"B49","doi-asserted-by":"publisher","first-page":":E8","DOI":"10.1111\/bju.13925","article-title":"Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial","volume":"120","author":"Sooriakumaran","year":"2017","journal-title":"BJU Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.kjms.2017.07.002","article-title":"Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis","volume":"33","author":"Sheng","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis","volume":"77","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103198","article-title":"First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings","volume":"157","author":"Ferro","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: Systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2021","journal-title":"Eur Urol Focus"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018","article-title":"Abiraterone acetate\/androgen deprivation therapy combination versus docetaxel\/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: A network meta-analysis on safety and efficacy","volume":"34","author":"Kassem","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4184","article-title":"A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer","volume":"10","author":"Tsaur","year":"2021","journal-title":"Cancer Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","article-title":"ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer","volume":"35","author":"Cato","year":"2019","journal-title":"Cancer Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432","article-title":"TP53 and prognosis in mCRPC survival: Biology or coincidence","volume":"25","author":"Rebello","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00430-4","article-title":"Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer","author":"Velez","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.003","article-title":"Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: Correlative analysis of the E3805 CHAARTED trial","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer","volume":"78","author":"Swami","year":"2020","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.913438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T04:43:28Z","timestamp":1660797808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.913438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":63,"alternative-id":["10.3389\/fonc.2022.913438"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.913438","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"913438"}}